Eradication Rates of Helicobacter Pylori and Its Affecting Factors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01922505|
Recruitment Status : Completed
First Posted : August 14, 2013
Last Update Posted : August 14, 2013
|Condition or disease||Intervention/treatment|
|Helicobacter Infections||Drug: PPI triple therapy|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||2500 participants|
|Target Follow-Up Duration:||4 Weeks|
|Official Title:||The Trend of Eradication Rates of First-line Triple Therapy for Helicobacter Pylori and Clinical Factors That Affect the Eradication in Korean: Single Center Experience for Recent Ten Years|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||May 2013|
|Actual Study Completion Date :||May 2013|
PPI triple therapy
7-day PPI triple therapy regimen: PPI (esomeprazole 40 mg or omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg or rabeprazole 20 mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
Drug: PPI triple therapy
- Eradication Rates of First-line Triple Therapy for Helicobacter pylori [ Time Frame: Four weeks after completing eradication therapy ]Non invasive H. pylori test (13C-urea breath test(UBT)) or invasive H. pylori test (Giemsa histology, Rapid Urease test) were performed after four weeks after completing eradication therapy.
- Clinical Factors that Affect the Eradication [ Time Frame: Four weeks after completing eradication therapy ]
Main variables are Cytochrome P450 2C19 (CYP2C19) genotype and Antibiotics resistance by H. pylori culture MICs result.
Other variables are age, gender, underlying disease (hypertension, diabetes, chronic liver, lung, kidney diseases), cigarette smoking and alcohol use.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01922505
|Korea, Republic of|
|Seoul National University Bundang Hospital|
|Bundang-gu, Seongnam, Gyeonggi-do, Korea, Republic of, 463-707|